Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 8,54€(+655,75%). Der Median liegt bei 8,54€(+655,75%).
| Kaufen | 3 |
| Halten | 0 |
| Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Longeveron® Appoints Than Powell as Chief Business Officer
Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program.» Mehr auf globenewswire.com
Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron® completes enrollment of pivotal Phase 2b clinical trial evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS).» Mehr auf globenewswire.com
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa'el Hashad, CEO, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025.» Mehr auf globenewswire.com
Unternehmenszahlen
| (EUR) | März 2025 | |
|---|---|---|
| Umsatz | 352,18k | 30,64% |
| Bruttoeinkommen | 254,20k | 260,98% |
| Nettoeinkommen | −4,63 Mio | 23,19% |
| EBITDA | −4,79 Mio | 34,67% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 16,95 Mio€ |
Anzahl Aktien | 15,01 Mio |
52 Wochen-Hoch/Tief | 5,46€ - 0,97€ |
| Dividenden | Nein |
Beta | 0,21 |
KGV (PE Ratio) | −1,17 |
KGWV (PEG Ratio) | −0,03 |
KBV (PB Ratio) | 1,15 |
KUV (PS Ratio) | 8,92 |
Unternehmensprofil
| Name | LONGEV.INC. NEW A DL-,001 Aktie |
| CEO | Mohamed Wa'el Ahmed Hashad |
| Mitarbeiter | 25 |
Assets entdecken
Shareholder von LONGEV.INC. NEW A DL-,001 Aktie investieren auch in folgende Assets
